Table 1 Description of the MORGAM cohorts
Number of individuals | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Cohort | Subcohorta | Incident cases outside subcohort | All | Non-cases | CHDb | Strokeb | Smokersc | Males | Age at baselined (years) | Follow-up median/max (years) |
FINRISK (Finland) | 700 (609/91) | 476 | 1176 | 609 (51.8%) | 382 (32.5%) | 185 (15.7%) | 285 (24.2%) | 827 (70.3%) | 57.0 [25–74] | 8.07/10.96 |
ATBC (Finland) | 849 (718/131) | 421 | 1270 | 718 (56.5%) | 343 (27.0%) | 209 (16.5%) | 1007 (79.3%) | 1270 (100%) | 63.4 [54–76] | 7.12/8.29 |
Sweden | 136 (128/8) | 59 | 195 | 128 (65.6%) | 29 (14.9%) | 38 (19.5%) | 37 (19.0%) | 121 (62.0%) | 55.8 [24–73] | 6.04/10.87 |
PRIME N.Ireland | 143 (135/8) | 108 | 251 | 135 (53.8%) | 103 (41.0%) | 13 (5.2%) | 66 (26.3%) | 251 (100%) | 54.9 [50–60] | 5.14/5.99 |
PRIME France | 188 (182/6) | 108 | 296 | 182 (61.5%) | 98 (33.1%) | 16 (5.4%) | 73 (24.7%) | 296 (100%) | 55.3 [49–60] | 5.28/7.61 |
Entire | 2016 (1772/244) | 1172 | 3188 | 1772 (55.6%) | 955 (30.0%) | 461 (14.5%) | 1468 (46.0%) | 2765 (86.7%) | 59.2 [24–76] | 6.33/10.96 |